hackint0sh/New-Dataset huggingface dataset:
Primary objective of this study is to assess the efficacy of JMT101 combined with Osimertinib versus Cisplatin combined with pemetrexed using by （Independent Review Center）IRC-assessed Progression Free Survival (PFS) per RECIST 1.1 as primary endpoint. Approximately 398 participants are estimated to be randomized into the study. Participants enrolled will be randomized to JMT101 or Cisplatin chemotherapy in a 1:1 manner, stratified by baseline brain metastasis (with/without) and Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) (0 versus 1). conditions: Local Advanced or Metastatic NSCLC studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 398 type: ESTIMATED name: JMT101 Injection name: Osimertinib tablet name: Cisplatin injection name: Pemetrexed injection measure: Progression Free Survival (PFS) as assessed by Independent Review Center (IRC) per RECIST 1.1 measure: Overall Survival (OS) measure: Overall Response Rate (ORR) by IRC per RECIST 1.1 measure: Duration of Response (DoR) by IRC per RECIST 1.1 measure: PFS by investigator per RECIST 1.1 measure: ORR by investigator per RECIST 1.1 measure: DoR by investigator per RECIST 1.1 sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06380322 id: PBRC 2023-034 briefTitle: Military Health and Nutrition Examination Study acronym: MHANES overallStatus: NOT_YET_RECRUITING date: 2024-06-01 date: 2026-12-01 date: 2026-12-01 date: 2024-04-23 date: 2024-04-23 name: Pennington Biomedical Research Center class: OTHER name: U.S. Army Medical Research and Development Command briefSummary: The Military Health and Nutrition Examination Study (MHANES) is a Department of Defense funded study conducted by Pennington Biomedical Research Center and the US Army Research Institute of Environmental Medicine. This cross-sectional study will assess, in a large, diverse sample of Army Service Members (n=600), food and supplement intake, cardiovascular health, body composition, biomarkers of nutritional status, measures of health status, injury prevalence, mental wellbeing, gut microbiome composition, and physical performance outcomes. The proposed study is modeled after the National Health and Nutrition Examination Survey (NHANES) and customized for the Army population. conditions: Hypertension conditions: Type 2 Diabetes conditions: Dyslipidemias conditions: Cardiovascular Diseases studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: CROSS_SECTIONAL count: 600 type: ESTIMATED measure: Dietary intake measure: Dietary quality measure: Depression measure: Anxiety measure: Resilience measure: Posttraumatic stress disorder measure: Self-efficacy measure: Mood measure: Physical activity measure: Physical activity measure: Physical performance measure: Physical injuries measure: Sleep duration and quality measure: Sleep duration and quality measure: Eating behavior (Satiety) measure: Eating behavior (Fast Eating Rate) measure: Eating behavior (Slow Eating Rate) measure: Blood pressure measure: Anthropometric and body composition measures measure: Measures of anemia and iron status, nutrient status, hormone status, stress, cardiometabolic health, and inflammation measure: Albumin, iodine, and other biomarkers of health measure: Gut microbiome composition measure: Prescription and over-the-counter medication and supplement use measure: Resting metabolic rate (RMR) measure: Heart rate variability (HRV) measure: Genomics sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Pennington Biomedical Research Center city: Baton Rouge state: Louisiana zip: 70808 country: United States name: Claire E Berryman, PhD, RD role: CONTACT email: claire.berryman@pbrc.edu lat: 30.45075 lon: -91.15455 hasResults: False
nctId: NCT06380309 id: LY001-I001 briefTitle: A Clinical Study on Evaluating Intravenous Administration of IDOV-SAFE overallStatus: RECRUITING date: 2024-05-06 date: 2025-11-30 date: 2027-10-30 date: 2024-04-23 date: 2024-04-23 name: Peking University class: OTHER briefSummary: Subjects were inoperable Chinese patients with histologically or cytologically confirmed advanced malignant solid tumors (mainly focusing on MSS type colorectal cancer) who had failed standard systemic therapy.
In the first stage, each subject was given three doses on day 1, day 3 and day 5, and was divided into 4 dose groups, including 1 subject in the first dose group and 3-6 subjects in each of the last three dose groups. The second stage was the dose extension stage, with 2 dose groups, at least 10 subjects were enrolled in the selected group, and the administration method was the same as that of the first stage. There were about 20-60 cases in the two stages. conditions: Advanced Malignant Solid Tumor of Digestive System studyType: INTERVENTIONAL phases: EARLY_PHASE1 allocation: NON_RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: INVESTIGATOR count: 60 type: ESTIMATED name: IDOV-SAFE measure: Occurrence of dose-limiting toxicity (DLT) measure: Incidence of adverse events (AE) measure: The level of (non-essential) viral DNA in tumor tissue measure: Tumor markers measure: Anti-vaccinia virus neutralizing antibody test(VV-Nab) measure: Levels of viral DNA in blood measure: Levels of viral DNA in saliva measure: T cell subsets measure: Cytokines measure: ORR measure: DCR measure: DOR measure: PFS measure: OS sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Beijing Cancer Hospital status: RECRUITING city: Beijing country: China name: Lin Shen role: CONTACT phone: +86 10 8819 6561 email: doctorshenlin@sina.cn lat: 39.9075 lon: 116.39723 hasResults: False
nctId: NCT06380296 id: 2024-10240 briefTitle: Outcomes of NeoMTA and NeoPUTTY Pulpotomies in Primary Molars overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2026-09 date: 2027-03 date: 2024-04-23 date: 2024-04-23 name: McGill University Health Centre/Research Institute of the McGill University Health Centre class: OTHER briefSummary: The goal of this clinical trial is to evaluate the outcomes of different medications used for pulpotomies (baby root canal) in children. The main question it aims to answer is: • what are the long-term clinical and radiographic success of pulpotomies in baby teeth using two different medications (NeoMTA and NeoPUTTY) over a 24-month follow-up period? Healthy children aged between 3 and 10 years undergoing dental treatment under general anesthesia who have deep caries lesions approximating or reaching the nerve will be invited to participate in this study. Pulpotomies (baby root canal) will be performed by trained dentists following a protocol. Children will receive pulpotomies either with NeoMTA or NeoPUTTY, two medications indicated for the procedure. Participants will be asked to come for an appointment at 1, 6, 12 and 24 months after the procedure. Researcher will compare the clinical and radiographic performance of pulpotomies (baby root canal) done with both medications. conditions: Pulp Disease, Dental studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 50 type: ESTIMATED name: Primary molars pulpotomies with NeoMTA name: Primary molar pulpotomies with NeoPUTTY measure: Success rate of a primary molar pulpotomy measure: Radiographic success of a primary molar pulpotomy sex: ALL minimumAge: 3 Years maximumAge: 10 Years stdAges: CHILD hasResults: False
nctId: NCT06380283 id: 2024-10221 briefTitle: The Feasibility and Clinical Utility of the Use of Virtual Reality for the Management of Pediatric Dental Anxiety overallStatus: RECRUITING date: 2024-03-21 date: 2025-07 date: 2026-01 date: 2024-04-23 date: 2024-04-23 name: McGill University Health Centre/Research Institute of the McGill University Health Centre class: OTHER briefSummary: The use of virtual reality (VR) in pediatric healthcare settings helps to reduce children's pain and anxiety. However, this technology has not been used consistently in pediatric dentistry. Consequently, the goal of this study is to investigate the effectiveness of using a Virtual Reality headset as a distraction technique during dental procedures in children and identify patient and clinician's opinions regarding its use.
This study incorporates a single-site, randomized clinical trial design with two paralleled study groups. One group will receive dental treatment following regular standard of care of behavior management while the second group will receive dental treatment using a Virtual Reality distraction headset. Patients in both groups will complete a questionnaire to assess their perception of pain and anxiety before and after the intervention, as well as their satisfaction with the dental treatment. The dentist providing the treatment will also report their observations relating to patient behavior during dental treatment. conditions: Children, Only conditions: Dental Anxiety conditions: Behavior studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: OTHER masking: NONE count: 128 type: ESTIMATED name: Virtual reality headset measure: Children's pain perception during dental treatment measure: Children's fear during dental treatment measure: Children's acceptability of virtual reality intervention during dental care measure: Oral health care provider's acceptability of virtual reality during dental care sex: ALL minimumAge: 6 Years maximumAge: 12 Years stdAges: CHILD facility: Division of Dentistry, Montreal Children's Hospital, McGill University Health Centre status: RECRUITING city: Montreal state: Quebec country: Canada name: Beatriz Ferraz dos Santos, DDS, MSc role: CONTACT phone: +1 (514) 412-4400 phoneExt: 23357 email: beatriz.ferrazdossantos@muhc.mcgill.ca lat: 45.50884 lon: -73.58781 hasResults: False
nctId: NCT06380270 id: LUMHS/B12/Temp/14.04.2024 briefTitle: Safety and Human Tolerance of Oral Probiotic Streptococcus Salivarius K12 overallStatus: NOT_YET_RECRUITING date: 2024-06-01 date: 2024-10-31 date: 2024-12-31 date: 2024-04-23 date: 2024-04-23 name: Liaquat University of Medical & Health Sciences class: OTHER briefSummary: Streptococcus salivarius K12, an oral probiotic strain, has emerged as a promising tool in promoting oral health. Found naturally in the mouth, S. salivarius K12 works by establishing itself in the oral cavity and producing antimicrobial compounds, such as bacteriocins, including salivaricin A2 (SalA2) and the 2,740-Da salivaricin B (SboB) lantibiotics, which inhibit the growth of harmful bacteria including Streptococcus pyogenes. By maintaining a healthy balance of oral microbiota, this probiotic may help prevent common oral health issues such as bad breath, throat infections, and tooth decay. While further research is needed to fully elucidate its mechanisms and efficacy, S. salivarius K12 holds potential as a natural and safe adjunct to oral hygiene practices for promoting overall oral health and hygiene. conditions: Strep Throat studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: DOUBLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 54 type: ESTIMATED name: Oral probiotic Streptococcus salivarius K12 sachet measure: Effect on oral health physical condition measure: Effect on other physical features measure: Effect on vital signs measure: Effect on vital signs measure: Effect on vital signs measure: Effect on vital signs measure: Effect on blood biochemistry measure: Effect on blood biochemistry measure: Effect on blood biochemistry measure: Effect on blood biochemistry measure: Effect on blood electrolytes balance measure: Effect on hematology measure: Incidence of inflammation measure: Incidence of gastrointestinal side effects measure: Incidence of Adverse events (AEs) sex: ALL minimumAge: 18 Years maximumAge: 60 Years stdAges: ADULT facility: Liaquat University of Medical and Health Sciences city: Jāmshoro zip: 76090 country: Pakistan name: Dr. Amjad Khan, DPhil role: CONTACT phone: 03000506955 email: amjadkhan@lumhs.edu.pk lat: 25.43773 lon: 68.28522 hasResults: False
nctId: NCT06380257 id: ANBA briefTitle: Anorexia Nervosa and Brain in Adolescence overallStatus: NOT_YET_RECRUITING date: 2024-09 date: 2030-08 date: 2030-12 date: 2024-04-23 date: 2024-04-23 name: Kuopio University Hospital class: OTHER briefSummary: Aims of this follow-up study are to investigate effects of anorexia nervosa on brain structure and functions in adolescence. conditions: Anorexia Nervosa studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: PROSPECTIVE count: 50 type: ESTIMATED name: Observational study methods measure: Neuroimaging measure: Neuroimaging measure: Psychiatric evaluation measure: Body composition measurement measure: Laboratory tests sex: ALL minimumAge: 16 Years maximumAge: 19 Years stdAges: CHILD stdAges: ADULT hasResults: False
nctId: NCT06380244 id: 1072.6120.136.2023 briefTitle: Opioid-free Anesthesia as an Alternative to General Anesthesia in Abdominal Surgery overallStatus: RECRUITING date: 2024-03-10 date: 2025-12-31 date: 2025-12-31 date: 2024-04-23 date: 2024-04-23 name: Jagiellonian University class: OTHER briefSummary: Due to the increasing number of reports of cancer progression in people undergoing surgery under general anesthesia using opioids, OFA is believed to have a favorable long-term prognostic effect, especially in cancer patients. The opioid-free protocol is also used in postoperative analgesia. It is estimated that up to 75% of surgical patients experience chronic postoperative pain, which has a particularly negative impact on the quality of life.
The investigators would like to compare pain during the first 48 postoperative hours of patients undergoing abdominal surgery who would be anesthetized with opioids and without opioids (patients would be randomly assigned to a group) (1, 2, 6, 12, 24 and 48 h after operations). A secondary objective will be to measure total oxycodone consumption in the postoperative period in both groups. Other secondary objectives: assessment of postoperative nausea and vomiting (PONV). conditions: Analgesics, Opioid conditions: Anesthesia, Endotracheal conditions: Anesthesia, General studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Parallel Assignment primaryPurpose: TREATMENT masking: SINGLE whoMasked: INVESTIGATOR count: 100 type: ESTIMATED name: anesthesia without opioids measure: Pain level measure: Total long acting opioid consumption in oxycodone equivalents sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Jagiellonian University status: RECRUITING city: Kraków state: Malopolskie zip: 31501 country: Poland name: Tomasz Skladzien, phd md role: CONTACT phone: 506602250 phoneExt: 48 email: t.skladzien@interia.pl lat: 50.06143 lon: 19.93658 hasResults: False
nctId: NCT06380231 id: IRU-YAZILE-001 briefTitle: Skin-to-skin Contact Between Premature Infant and Mother overallStatus: COMPLETED date: 2019-11-01 date: 2019-12-01 date: 2020-12-01 date: 2024-04-23 date: 2024-04-23 name: Istanbul Rumeli University class: OTHER briefSummary: Aim: To determine the effect of kangaroo mother care (KMC) on perfusion index, heart rate, and oxygen saturation in premature infants who were discharged early and admitted to the neonatal intensive care in the following days. conditions: Kangaroo-mother Care studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: SUPPORTIVE_CARE masking: DOUBLE whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 76 type: ACTUAL name: kangaroo mother care (KMC) measure: power analysis measure: The effect of kangaroo mother care sex: ALL minimumAge: 24 Weeks maximumAge: 37 Weeks stdAges: CHILD facility: TC Istanbul Rumeli University city: Istanbul state: Haliç zip: 34445 country: Turkey lat: 41.01384 lon: 28.94966 hasResults: False
nctId: NCT06380205 id: INCB54707-111 briefTitle: A Study to Evaluate the Drug Interaction Between Povorcitinib and the Oral Contraceptive Levonorgestrel/Ethinyl Estradiol in Healthy Adult Females overallStatus: RECRUITING date: 2024-05-07 date: 2024-06-07 date: 2024-06-07 date: 2024-04-23 date: 2024-04-24 name: Incyte Corporation class: INDUSTRY briefSummary: The purpose of this study is to evaluate the drug interaction between povorcitinib and the oral contraceptive levonorgestrel/ethinyl estradiol in healthy adult females. conditions: Healthy Participants studyType: INTERVENTIONAL phases: PHASE1 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 24 type: ESTIMATED name: Povorcitinib name: Levonorgestrel/Ethinyl estradiol measure: Levonorgestrel (LNG) concentration in plasma measure: Ethinyl estradiol (EE) concentration in plasma measure: Number of participants with Treatment-emergent Adverse Events (TEAEs) measure: Additional LNG/EE PK parameters in plasma measure: Povorcitinib concentration in plasma sex: FEMALE minimumAge: 18 Years maximumAge: 60 Years stdAges: ADULT facility: Celerion Clinical Research Unit status: RECRUITING city: Tempe state: Arizona zip: 85283 country: United States lat: 33.41477 lon: -111.90931 hasResults: False
nctId: NCT06380192 id: HJ22-DEE-RETRO briefTitle: Developmental and Epileptic Encephalopathy of Genetic Etiology: Natural History Through Reuse of Clinical Data acronym: DEE-RETRO overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2026-03-31 date: 2026-03-31 date: 2024-04-23 date: 2024-04-23 name: Imagine Institute class: OTHER briefSummary: Developmental and Epileptic Encephalopathy (DEE) are a heterogeneous group of neurodevelopmental disorders linked to both epilepsy and its underlying etiology, independently of epileptiform activity.
The creation of a database with retrospective follow-up of a large number of patients on a national scale will enable better knowledge of specific biomarkers, and thus a better classification and understanding of the natural evolution of DEE according to their etiology. This will enable better, more personalized therapeutic management of patients, depending on etiology and the presence or absence of these biomarkers. The investigators will also be able to draw up management recommendations, which are currently non-existent. conditions: Developmental and Epileptic Encephalopathy studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: CROSS_SECTIONAL count: 400 type: ESTIMATED measure: Identification of early diagnostic of a neurodevelopmental trajectory in children with epileptic and developmental encephalopathies measure: Identification of predictive biomarkers of a neurodevelopmental trajectory in children with epileptic and developmental encephalopathies measure: Identification of patient subgroups presenting the identified biomarkers measure: Assessment of patients' quality of life measure: Assessment of age-related adaptive behavior measure: Assessment of behavioral disorders measure: Assessment of autism spectrum disorders sex: ALL maximumAge: 17 Years stdAges: CHILD hasResults: False
nctId: NCT06380179 id: USUHS.2023-126 briefTitle: Photomedicine Project 14: PBMT for Performance Enhancement in SOF acronym: SOF overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2025-08 date: 2026-01 date: 2024-04-23 date: 2024-04-23 name: Musculoskeletal Injury Rehabilitation Research for Operational Readiness (MIRROR) class: UNKNOWN name: Uniformed Services University (USU) of the Health Sciences name: 1st Special Forces Group (Airborne), United States Army name: United States Army Special Operations Command name: The Geneva Foundation briefSummary: Special Operations Forces (SOF) train continually to maintain peak performance. Thus, they are nearly always in a state of recovery, and in need of noninvasive therapies to address the taxing workload. Photobiomodulation therapy (PBMT) is a noninvasive treatment where a low-level laser is applied to the body to enhance healing, recovery, and performance. Army Tactical Human Optimization Rapid Rehabilitation and Reconditioning (THOR3) provides a consistent avenue for implementation of PBMT as a modality. Studies in athletes have shown performance and recovery benefits with pre-and post-workout focal application of PBMT. While there is less evidence on the potential cognitive/behavioral effects of a systematic application of PBMT, self-reported fatigue has also been found to be significantly lower in groups with focal PBMT application as compared to placebo. Further, PBMT research in healthy military tactical athletes is limited. PBMT may be a promising tool for enhancing physical performance by accelerating musculoskeletal and psychological recovery in the SOF population. The investigators aim to study the physiologic and behavioral effects of PBMT application post-exercise on performance in SOF Operators.
nctId: NCT06380166 id: A23-356 briefTitle: Hepatitis C Lab Testing Comparison Study overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2024-07 date: 2024-09 date: 2024-04-23 date: 2024-04-23 name: HealthPartners Institute class: OTHER briefSummary: Hepatitis C (HCV) HCV antibody assays are the standard of care test used to screen for HCV, but confirmation of acute infection is relegated in the current US guidelines to polymerase chain reaction (PCR) which often takes multiple days and may result in a loss to follow up and treatment, especially in high prevalence populations. HCV core antigen is a new, research use only immunoassay intended for use on the Abbott Alinity i system, an FDA-cleared instrument for clinical chemistry and immunoassay testing. The aim of the study is to evaluate the 48-hour stability of HCV core antigen in fresh serum and plasma specimens collected from individuals with a detectable HCV viral load (HCL VL), as per a recent antibody assay test, under multiple specimen storage conditions mirroring those employed in clinical laboratories. conditions: Hepatitis C studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: DIAGNOSTIC masking: NONE count: 25 type: ESTIMATED name: Hepatitis C core antigen measure: Serum on the clot stability measure: Serum off the clot stability measure: Plasma on the gel stability measure: Plasma off the gel stability sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06380153 id: HM005PS1S07 briefTitle: To Evaluate the Pharmacokinetics of Hemay005 Tablets in Patients With Renal Impairment overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2024-12 date: 2024-12 date: 2024-04-23 date: 2024-04-23 name: Ganzhou Hemay Pharmaceutical Co., Ltd class: INDUSTRY briefSummary: The aim of this study was to evaluate the pharmacokinetics of Hemay005 tablets in subjects with mild to moderate renal impairment and normal renal function, and to provide a basis for the formulation of clinical medication regimens for patients with renal impairment. conditions: Psoriasis studyType: INTERVENTIONAL phases: PHASE1 allocation: NON_RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 24 type: ESTIMATED name: Hemay005 measure: Relevant pharmacokinetic parameters，Peak Plasma Concentration（Cmax） measure: Relevant pharmacokinetic parameters，Area under the plasma concentration versus time curve（AUC0-t） measure: Relevant pharmacokinetic parameters，Area under the curve from time 0 extrapolated to infinite time (AUC0-inf) measure: Relevant pharmacokinetic parameters，half-life (T1/2) measure: Relevant pharmacokinetic parameters，clearance (CL/F) measure: Relevant pharmacokinetic parameters，volume of distribution (Vz/F) measure: Relevant pharmacokinetic parameters ，Renal clearance rate（CLr） sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False